In this episode, Eoin Tabb, a clinical cancer services pharmacist, unravels the complexities of immune checkpoint inhibitors (ICIs), the superheroes of cancer therapy. We'll explore how ICIs unleash the immune system to fight cancer, the potential side effects known as immune-related adverse events, and how healthcare professionals can effectively manage them. From common skin reactions and endocrine disruptions to rare neurological and cardiac complications, we'll cover it all. Tune in to understand how ICIs are revolutionizing cancer treatment while being prepared for their unique challenges

• Introduction: Immune checkpoint inhibitors (ICIs) as revolutionary cancer treatments.
• What are ICIs? How ICIs work by removing cancer's "invisibility cloak" to the immune system.
• Immune-Related Adverse Events (irAEs): Explanation of irAEs as a side effect of overactive immune response.
• Common irAEs:
• Other irAEs: Neurological, cardiovascular, renal, hematologic, ocular.
• Overlapping Syndromes: Myocarditis-myositis overlap, myasthenia gravis.
• Management of irAEs:
• Long-Term Management: Ongoing monitoring for late-onset or recurrent irAEs.
• Emerging Therapies: Targeted therapies, personalized medicine.
• Important Disclaimer: Consult healthcare providers for personalized guidance.

CPD IIOP Example: https://docs.google.com/document/d/1lI2B0iiLxYAHkvkWo8AjHvw-fjnCwc4DcioSiVF4Ptw/edit?usp=sharing

Feedback Form: https://forms.gle/AEcFAHCnykCNkKDJ9

References:

ESMO Guidelines: https://www.annalsofoncology.org/article/S0923-7534(22)04187-4/fulltext